INBRX-106 Combination Doubles Response Rate in Early HNSCC Study, Showing Clear Clinical Benefit Over Standard PD-1 Monotherapy
Market Chameleon (Mon, 11-May 8:16 AM)
INBX Highlights: Ozekibart Shows Robust Disease Control Rate of 87% in Late-Line Colorectal Cancer—Durable Responses Outpace Historical Norms
Market Chameleon (Wed, 22-Apr 10:28 AM)
INBX’s Ozekibart Delivers 20% Response Rate and 87% Disease Control in Late-Line Colorectal Cancer—Durable Results in Tough-to-Treat Patients
Market Chameleon (Wed, 22-Apr 7:34 AM)
